
Hormone Therapy
Testosterone Replacement Therapy and Longevity
Testosterone replacement therapy (TRT) is an evidence-based treatment for men with symptoms and consistently low morning testosterone levels.
It can improve sexual function and may modestly improve mood in this group. Evidence does not show that TRT prevents cardiovascular disease, diabetes, fractures, or early death.
Using testosterone to “optimize” a normal level is not a guideline-supported indication and has not been tested for longevity.
- Reading time
- 9 min
- Source last reviewed
- 22 Jul 202622 Jul 2026
- Last updated
- 31 Aug 202631 Aug 2026
Reader compass
What a responsible TRT plan covers
The diagnosis
Symptoms must be considered with repeat morning testosterone tests and an evaluation for reversible or underlying causes.
The treatment goal
Define which symptoms should improve and understand that raising a laboratory value does not prove a longevity benefit.
The safety plan
Follow testosterone level, hematocrit, blood pressure, prostate context, fertility goals, and sleep-apnea risk.
TRT discussions often begin with fatigue, lower desire, erectile changes, mood, or reduced strength. Those symptoms are common and can have many causes.
A careful evaluation determines whether testosterone deficiency is present and whether treatment is likely to address the problem.
How TRT differs from performance dosing
Testosterone is a steroid hormone made primarily in the testicles. It supports sexual function, muscle and bone, red-blood-cell production, and other body systems.
TRT replaces testosterone when a clinical deficiency causes symptoms or signs.
TRT aims to restore levels to a normal physiologic range under medical supervision. Performance-enhancing use typically involves higher doses or combinations intended to produce levels beyond the normal range.
Both involve a steroid hormone, but the dose, goal, evidence, and risk context differ.
Clinical trials and guidelines focus on men with symptoms and confirmed low levels. The Endocrine Society recommends against prescribing testosterone for age-related decline alone 1.
Evidence is insufficient to say that raising a normal testosterone level improves healthspan or lifespan. If a clinic offers “optimization,” ask what diagnosis and outcome support the prescription.
Routes and fertility-preserving options
| Format | What it usually means | Trade-offs to weigh |
|---|---|---|
| Injection | Testosterone is injected on a regular schedule. | Levels can vary between doses. Injections may raise hematocrit more than gels and require comfort with needles. |
| FDA-approved gel | Testosterone is applied to the skin every day. | Absorption varies, and the medicine can transfer to a partner or child through skin contact. Compounded creams are a separate category. |
| Pellets | Small pellets are placed under the skin every few months. | Placement requires a minor procedure, and the dose cannot be reduced quickly after insertion. |
| Oral | Newer testosterone capsules are taken by mouth. | Instructions vary by product. Oral therapy still requires testosterone, hematocrit, and blood-pressure monitoring. |
| Fertility-preserving approaches | Medicines such as hCG (human chorionic gonadotropin) or clomiphene stimulate the body's own pathway. | These are separate from TRT and may be considered when fertility matters. Evidence, approval status, and suitability depend on the drug and diagnosis 2. |
Formulation choice comes after the diagnosis. The dose is adjusted using symptoms, a properly timed testosterone level, adverse effects, and hematocrit 1. Cost and daily burden also matter.
If near-term fertility is a goal, discuss it before the first dose because standard TRT suppresses sperm production.

What men notice on TRT
In the Testosterone Trials, older men with low testosterone had modest improvements in sexual activity, desire, and erectile function 3.
Sexual symptoms have some of the best treatment evidence, although erectile dysfunction can still require evaluation for vascular, medication, or psychological causes.
Mood and depressive symptoms improved slightly in the same program 3. Its primary vitality measure did not improve, so energy should not be promised as a reliable result.
Fatigue that persists on TRT deserves evaluation for sleep, mood, anemia, thyroid disease, medication effects, and other causes.
Define the treatment goal before starting and record a baseline. At follow-up, review the symptoms that supported the diagnosis rather than judging treatment by the testosterone result alone.
A higher value without meaningful improvement should prompt reconsideration of the dose, diagnosis, or plan.
What TRT means for heart, bone, and lifespan
TRT can improve a measurement without improving the clinical outcome that matters. In imaging studies, testosterone increased spine bone density and estimated strength 5.
In a larger fracture analysis, 3.5% of men receiving testosterone had a clinical fracture compared with 2.5% receiving placebo 6. TRT should not be used as a fracture-prevention treatment.
| Outcome | What the trials found | Dimension | What not to overread |
|---|---|---|---|
| Major cardiovascular events | TRAVERSE found testosterone noninferior to placebo in men with symptoms, low testosterone, and existing or elevated cardiovascular risk 4. | Healthspan | Noninferiority supports cardiovascular safety in the studied population. It does not show cardiovascular benefit. |
| Other cardiovascular findings | Atrial fibrillation, acute kidney injury, and pulmonary embolism occurred more often with testosterone 4. | Healthspan | These were secondary findings and still belong in risk counseling. |
| Bone | Bone density and estimated strength improved 5, but clinical fractures were more frequent with testosterone 6. | Healthspan | Do not assume that a better scan means fewer fractures. |
| Blood sugar | Testosterone did not prevent progression from prediabetes to diabetes 7. | Healthspan | TRT is not a diabetes-prevention or metabolic treatment. |
| Sexual function and energy | Sexual function improved modestly, while the primary vitality measure did not 3. | Wellspan | Set expectations by outcome instead of promising a general boost. |
| Living longer | No randomized trial has shown that TRT extends life. Low natural levels are associated with mortality in observational data 8. | Lifespan | An association does not show that treatment changes lifespan. |
TRAVERSE was designed to test cardiovascular safety, not cardiovascular benefit. It enrolled men with symptoms, repeatedly low testosterone, and existing or elevated cardiovascular risk.
Major cardiovascular events occurred at similar rates in the testosterone and placebo groups 4. The result should not be generalized to unscreened use, supraphysiologic dosing, or men without confirmed deficiency.
In 2025, the FDA removed its boxed warning about increased cardiovascular risk after reviewing TRAVERSE.
It retained the limitation on use for age-related decline and added a class-wide warning that testosterone can increase blood pressure 9. No trial has established a lifespan benefit.
Observational associations between low testosterone and mortality cannot show that TRT prevents death 8.
Confirming testosterone deficiency
Symptoms that fit
Low desire, fewer spontaneous erections, erectile changes, reduced muscle, anemia, or low bone density may support evaluation. Fatigue and low mood are less specific.
A repeat morning testosterone
Confirm a low result with a second fasting, early-morning test on a separate day. Symptoms plus consistently low levels are required 1.
Free testosterone when it matters
When total testosterone is borderline or SHBG is altered, a reliable free-testosterone estimate or measurement can clarify the result. Direct free-testosterone immunoassays are inaccurate 11.
LH and FSH
Luteinizing hormone (LH) and follicle-stimulating hormone (FSH) help distinguish a testicular cause from a pituitary or hypothalamic cause.
Baseline labs before a prescription
Before starting, check hematocrit, blood pressure, prostate context when appropriate, cardiometabolic risk, sleep apnea, and fertility goals.
Hypogonadism means relevant symptoms or signs together with unequivocally and consistently low morning testosterone 1.
The American Urological Association uses total testosterone below 300 ng/dL as a reasonable diagnostic cutoff 10.
A harmonized reference range in healthy young men placed its lower limit near 264 ng/dL 12. That reference limit is not a universal treatment threshold.
Results must be interpreted with the laboratory method, symptoms, and clinical context.
Poor sleep, obesity, acute illness, heavy alcohol use, some medications, and untreated sleep apnea can affect testosterone or cause similar symptoms.
Addressing reversible factors may improve health whether or not TRT is prescribed.
What's the difference between free and total testosterone?
Total testosterone includes free hormone and hormone bound to proteins. Free testosterone is the unbound fraction.
It can help when total testosterone is near the lower limit or sex hormone-binding globulin (SHBG) is altered.
Use a validated calculation or reliable measurement method rather than a direct immunoassay 11.
Monitoring a TRT plan
| What to watch | Why it matters | What triggers a change |
|---|---|---|
| Hematocrit | Hematocrit is the percentage of blood volume made up of red blood cells. TRT can raise it and cause erythrocytosis 13. | A baseline above about 48% warrants evaluation 11. A level of 54% during treatment calls for a pause or dose reduction 10. |
| Prostate context | PSA is a prostate-related blood marker. In screened trial participants, TRT did not significantly increase high-grade prostate cancer 14. A broader review found no significant difference in prostate cancer or PSA 15. | A meaningful PSA rise or exam change can require urology review. The trial excluded men with higher baseline PSA, so its reassurance is not universal. |
| Estradiol | Some testosterone converts to estradiol. Major guidelines do not recommend routine estradiol testing or routine estrogen-blocker use with standard TRT. | Test when symptoms or a specific clinical question justify it instead of treating a target number routinely. |
| Blood pressure | The FDA added a class-wide warning that testosterone products can increase blood pressure 9. | Measure blood pressure before treatment and during follow-up. Address a sustained rise. |
| Symptoms and testosterone level | Symptoms show whether treatment is helping. A properly timed testosterone result shows whether exposure is in the intended range. | Lack of improvement or an out-of-range result should prompt review of the dose, formulation, adherence, or diagnosis. |
| Sleep apnea | The Endocrine Society recommends against starting TRT in untreated severe obstructive sleep apnea (OSA) 1. Evidence about TRT worsening OSA is limited 16. | Evaluate and treat suspected severe OSA before starting. Reassess snoring, witnessed pauses, or daytime sleepiness during treatment. |
TRT can correct anemia in some men with hypogonadism 17, yet it can also push hematocrit too high.
Monitoring should include the treatment goal, testosterone level, hematocrit, blood pressure, adverse effects, and prostate assessment when appropriate.
A DEXA scan is based on bone risk rather than required for every TRT user. The blood-biomarkers guide explains other common tests.
TRT and fertility
Exogenous testosterone, meaning testosterone taken as medication, suppresses the hormone signals that support sperm production 2. Sperm counts can fall substantially or reach zero.
Recovery after stopping varies in timing and completeness.
The Endocrine Society recommends against TRT for men planning fertility in the near term 1.
Alternatives such as hCG or clomiphene may be considered under specialist care, depending on the cause of low testosterone 2.
Discuss semen testing and fertility preservation before starting rather than after a problem appears.
TRT can be stopped with medical guidance, but testosterone levels and symptoms may return toward baseline. Endogenous production and fertility may take time to recover.
Starting treatment therefore requires a long-term plan, even though continued use should be reassessed rather than assumed.
Where TRT fits in a longevity plan
TRT can improve specific symptoms in men with confirmed hypogonadism. It should not be treated as a general longevity intervention or prescribed solely to optimize a normal laboratory value.
No randomized trial has shown that TRT extends life.
Confirm symptoms and repeat morning levels before treatment. Evaluate reversible causes, discuss fertility, and agree on monitoring.
Low testosterone is associated with earlier death in observational data 8, but that association does not prove that raising testosterone changes lifespan.
Related guides cover thyroid evaluation, menopause hormone therapy, and peptides marketed for growth-hormone support.
Look for a clinician who diagnoses testosterone deficiency according to guidelines, discusses fertility before prescribing, and provides scheduled follow-up.
Ask how the service handles high hematocrit, rising blood pressure, lack of symptom improvement, and referrals for prostate or fertility concerns.
Sources and references17 sources
- 1
Bhasin S, Brito JP, Cunningham GR, et al. "Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline." Journal of Clinical Endocrinology & Metabolism. 2018. JCEM ↑
- 2
Crosnoe LE, Grober E, Ohl D, Kim ED. "Exogenous testosterone: a preventable cause of male infertility." Translational Andrology and Urology. 2013. PubMed ↑
- 3
Snyder PJ, Bhasin S, Cunningham GR, et al. "Effects of Testosterone Treatment in Older Men." New England Journal of Medicine. 2016. PubMed ↑
- 4
Lincoff AM, Bhasin S, Flevaris P, et al. "Cardiovascular Safety of Testosterone-Replacement Therapy." New England Journal of Medicine. 2023. PubMed ↑
- 5
Snyder PJ, Kopperdahl DL, Stephens-Shields AJ, et al. "Effect of Testosterone Treatment on Volumetric Bone Density and Strength in Older Men With Low Testosterone." JAMA Internal Medicine. 2017. PubMed ↑
- 6
Snyder PJ, Bauer DC, Ellenberg SS, et al. "Testosterone Treatment and Fractures in Men with Hypogonadism." New England Journal of Medicine. 2024. PubMed ↑
- 7
Bhasin S, Lincoff AM, Nissen SE, et al. "Effect of Testosterone on Progression From Prediabetes to Diabetes in Men With Hypogonadism." JAMA Internal Medicine. 2024. PubMed ↑
- 8
Yeap BB, et al. "Associations of Testosterone and Related Hormones With All-Cause and Cardiovascular Mortality and Incident Cardiovascular Disease in Men: Individual Participant Data Meta-analyses." Annals of Internal Medicine. 2024. PubMed ↑
- 9
U.S. Food and Drug Administration. "FDA issues class-wide labeling changes for testosterone products." 2025. FDA ↑
- 10
American Urological Association. "Evaluation and Management of Testosterone Deficiency: AUA Guideline." Journal of Urology. 2018. AUA ↑
- 11
VA Pharmacy Benefits Management Services / National Formulary Committee. "Testosterone Replacement Therapy (TRT) in Males: Criteria for Use." 2025. VA ↑
- 12
Travison TG, Vesper HW, Orwoll E, et al. "Harmonized Reference Ranges for Circulating Testosterone Levels in Men of Four Cohort Studies." Journal of Clinical Endocrinology & Metabolism. 2017. JCEM ↑
- 13
Cervi A, Balitsky AK. "Testosterone use causing erythrocytosis." Canadian Medical Association Journal. 2017. PMC ↑
- 14
Bhasin S, et al. "Prostate Safety Events During Testosterone Replacement Therapy in Men With Hypogonadism." JAMA Network Open. 2023. JAMA Network Open ↑
- 15
Xu Z, Chen X, Zhou H, et al. "An updated systematic review and meta-analysis of the effects of testosterone replacement therapy on erectile function and prostate." Frontiers in Endocrinology. 2024. Frontiers in Endocrinology ↑
- 16
Graziani A, Grande G, Ferlin A. "The complex relation between obstructive sleep apnoea syndrome, hypogonadism and testosterone replacement therapy." Frontiers in Reproductive Health. 2023. PubMed ↑
- 17
Pencina KM, Travison TG, Artz AS, et al. "Efficacy of Testosterone Replacement Therapy in Correcting Anemia in Men With Hypogonadism." JAMA Network Open. 2023. PubMed ↑
Build your starting plan.
A few short questions, about two minutes. The Blueprint recommends where to start and explains why.
Build my Blueprint